Provention Bio, a Sanofi Company
Sanofi US is an R&D-driven biopharmaceutical organization operating across research, vaccine and medicine development, large-scale manufacturing, and patient support programs. The U.S. operations emphasize vaccine and biologics production, DSCSA-compliant supply chain traceability, investment in domestic manufacturing capacity, and programs to support patient access and affordability.
Industries
Nr. of Employees
Very Large (1000+)
Provention Bio, a Sanofi Company
Products
Vaccines for multiple infectious diseases
Vaccine portfolio offering protection against diseases across the lifespan, including influenza, RSV and other infectious diseases.
Specialty and general medicines
Therapeutic medicines across specialty areas (immunology, neurology, oncology, rare diseases, rare blood disorders) and general medicine areas (diabetes, cardiovascular, transplant).
Vaccines for multiple infectious diseases
Vaccine portfolio offering protection against diseases across the lifespan, including influenza, RSV and other infectious diseases.
Specialty and general medicines
Therapeutic medicines across specialty areas (immunology, neurology, oncology, rare diseases, rare blood disorders) and general medicine areas (diabetes, cardiovascular, transplant).
Services
Programs to reduce out-of-pocket costs, copay assistance, patient assistance programs providing free medication to eligible patients, and live support specialists reachable by phone.
End-to-end manufacturing capabilities for vaccines and biologics including formulation, fill-finish, and facility-based pandemic preparedness production.
Provision of lot- and serial-level traceability data, portal access for ATP validation, and verification/trace request handling to support compliance.
Preparation and submission of remarks and public comment letters to advisory committees and regulatory stakeholders on vaccine and product policy topics.
Programs to reduce out-of-pocket costs, copay assistance, patient assistance programs providing free medication to eligible patients, and live support specialists reachable by phone.
End-to-end manufacturing capabilities for vaccines and biologics including formulation, fill-finish, and facility-based pandemic preparedness production.
Provision of lot- and serial-level traceability data, portal access for ATP validation, and verification/trace request handling to support compliance.
Preparation and submission of remarks and public comment letters to advisory committees and regulatory stakeholders on vaccine and product policy topics.
Expertise Areas
- Vaccine development and manufacturing
- Biologics and recombinant protein production
- mRNA research and platform development
- Clinical trial design and inclusivity
Key Technologies
- mRNA platform technologies
- Recombinant drug substance manufacturing
- Formulation and sterile fill-finish
- GMP manufacturing systems
News & Updates
Announcement to invest at least $20 billion in the U.S. through 2030 to grow science and expand domestic manufacturing.
Completion of a state-of-the-art formulation and filling facility and FDA approval of a new recombinant drug substance facility at the Swiftwater, PA campus; partnership with a U.S. government agency for pandemic preparedness.
Article describing use of AI and community partnerships to advance inclusivity in clinical trials.
Manufacturing operations in the U.S. produce more than 600 million medication units annually and employ over 3,400 manufacturing professionals.
$700 million invested in U.S. manufacturing capabilities over the prior five years (with ongoing investments planned).
Received a $10.65 million grant to modernize facility operations and reduce industrial sector emissions at a vaccine campus.
Announcement to invest at least $20 billion in the U.S. through 2030 to grow science and expand domestic manufacturing.
Completion of a state-of-the-art formulation and filling facility and FDA approval of a new recombinant drug substance facility at the Swiftwater, PA campus; partnership with a U.S. government agency for pandemic preparedness.
Article describing use of AI and community partnerships to advance inclusivity in clinical trials.
Manufacturing operations in the U.S. produce more than 600 million medication units annually and employ over 3,400 manufacturing professionals.
$700 million invested in U.S. manufacturing capabilities over the prior five years (with ongoing investments planned).
Received a $10.65 million grant to modernize facility operations and reduce industrial sector emissions at a vaccine campus.